Skip to main content
PureTech Health plc logo

PureTech Health plc — Investor Relations & Filings

Ticker · PRTC ISIN · GB00BPVG5C82 LEI · 213800LVPDNO2Z9T9I39 IL Manufacturing
Open in API
Filings indexed 1,320 across all filing types
Latest filing 2021-09-10 Regulatory Filings
Country GB United Kingdom
Listing IL PRTC

About PureTech Health plc

https://puretechhealth.com/

PureTech Health is a clinical-stage biotherapeutics company dedicated to discovering, developing, and commercializing new classes of medicine for devastating diseases. The company's research and development engine focuses on advancing novel treatments by enhancing on-target efficacy, improving tolerability, or enabling oral administration of therapeutics with validated mechanisms. Its pipeline includes wholly-owned therapeutic candidates targeting a range of conditions, including idiopathic pulmonary fibrosis, neuropsychiatric disorders, and various cancers.

Recent filings

Filing Released Lang Actions
PRTC's Vor Granted FDA Fast Track Designation
Regulatory Filings Classification · 100% confidence The document is distributed via RNS (RNS Number : 3390L) and is explicitly identified as being provided by 'Reach, the non-regulatory press release distribution service of RNS'. The content announces a clinical development milestone (FDA Fast Track Designation) for a subsidiary's drug candidate (Vor Biopharma's VOR33). This type of announcement, which is a press release about business/clinical progress rather than a mandatory financial filing (like 10-K, IR, or ER), fits best into the general regulatory/news announcement category. Since it is a press release distributed through the RNS system but explicitly marked as non-regulatory news by 'Reach', the most appropriate classification is 'Regulatory Filings' (RNS) as the general catch-all for such announcements that aren't covered by more specific codes like ER or CT, or 'Report Publication Announcement' (RPA) if it were announcing the release of a formal report. Given the content is a direct announcement of an event/designation, RNS is the best fit among the available options for general news releases distributed via this channel.
2021-09-10 English
Total Voting Rights
Share Issue/Capital Change Classification · 99% confidence The document is titled 'Total Voting Rights and Share Capital - Month End Disclosure' and explicitly references 'RNS Number : 2820K' and compliance with 'DTR 5.6.1 of the Disclosure Guidance and Transparency Rules'. It provides a specific update on the total number of voting rights and issued share capital as of August 31, 2021. This type of mandatory periodic disclosure regarding share structure and voting rights is typically classified under general regulatory announcements. Since there is no specific category for 'Total Voting Rights Disclosure', and it is a formal regulatory announcement distributed via RNS, the most appropriate classification is the general regulatory filing category, RNS. The document length is short (under 5,000 characters) and serves as a direct notification, not a comprehensive report.
2021-09-01 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by PureTech Health plc, which is a report of a foreign private issuer submitted pursuant to the Securities Exchange Act of 1934. The text indicates that the Form 6-K includes as an exhibit a press release titled 'PureTech Health plc – Half-Year Report'. The document itself is short (1739 characters) and primarily serves to announce the attached half-year report press release. According to the 'MENU VS MEAL' rule, since this document is short and only announces the report (the half-year report), it should be classified as a Regulatory Filing (RNS) rather than the actual Interim/Quarterly Report (IR).
2021-08-24 English
Half-year Report
Interim / Quarterly Report Classification · 100% confidence The document is a 'Half-Year Report' for PureTech Health plc for the period ended June 30, 2021. It contains substantive financial data, including cash and cash equivalents, and detailed operational updates on the company's pipeline and founded entities. It is not a mere announcement of a report (RPA) as it provides the actual content of the interim results. Therefore, it is classified as an Interim / Quarterly Report. H1 2021
2021-08-24 English
PRTC Presents LYT-100 Ph1 PK & Tolerability at ERS
Regulatory Filings Classification · 99% confidence The document begins with an RNS Number (3855J) and is dated August 23, 2021. The content describes the presentation of Phase 1 clinical trial data for a drug candidate (LYT-100) at a medical congress (ERS International Congress 2021). It includes scientific results, updates on ongoing Phase 2 trials, and forward-looking statements. This structure—announcing clinical data presentation and providing key results—is characteristic of a press release intended for investors and regulatory disclosure. The footer explicitly mentions that the information is provided by 'Reach, the non-regulatory press release distribution service of RNS.' While it is an RNS distribution, the content itself is a press release announcing clinical trial progress, which is often categorized as a general regulatory announcement or a specific type of investor communication. Since it is not a formal financial report (10-K, IR, ER) but a specific announcement distributed via the RNS system, and it doesn't fit other specific categories like DIV, CAP, or MANG, the most appropriate general category for a non-regulatory press release distributed via RNS is 'Regulatory Filings' (RNS) as a catch-all for such announcements, or potentially 'Investor Presentation' (IP) if the focus was purely on the presentation material, but here it is an announcement *about* the presentation. Given the context of RNS distribution and the nature of the announcement (clinical data update), RNS is the best fit among the provided options for a general regulatory/news announcement.
2021-08-23 English
Akili Deal Furthers Digital Medicine Leadership
M&A Activity Classification · 99% confidence The document begins with an RNS Number (8194I) and is dated August 17, 2021. The content describes a strategic licensing agreement between PureTech Health's founded entity, Akili, and TALi regarding digital therapeutics technology. This is a corporate announcement detailing a business development/partnership. It is not a full annual report (10-K), an earnings release (ER), or a formal proxy statement (DEF 14A). Since it is a specific corporate announcement distributed via RNS (London Stock Exchange's regulatory news service) that details a significant business transaction (licensing agreement/partnership), it fits best under the general 'Regulatory Filings' category (RNS) as a standard press release, or potentially 'Capital/Financing Update' (CAP) if the focus was purely on the financial structure, but RNS is the most appropriate catch-all for non-standard, material press releases distributed through this channel. Given the structure and the explicit mention of RNS distribution, RNS is the most accurate classification for this type of material announcement.
2021-08-17 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.